Mesoblast Limited (MSB) Earnings Call Transcripts

Mesoblast Limited's Latest Earnings Call - April 8, 2026

In the fiscal third quarter of 2026, Mesoblast Limited reported net revenues of $30.3 million, reflecting a strong commercial uptake of its FDA-approved product, Ryoncil. Management indicated that total revenues since the product's launch have approached $100 million. The company is optimistic about doubling revenues as it expands into adult indications for graft versus host disease and prepares for pivotal trials in chronic low back pain, with a potential BLA filing expected in Q3 2027. Overall, the company maintains a disciplined cash management strategy, projecting full fiscal year revenues between $110 million and $120 million while controlling costs effectively.

Reported metrics

Guidance from management

Management expects to double revenues from Ryoncil and projects full fiscal year net revenues between $110 million and $120 million, maintaining a disciplined approach to cash management.

What management said

So I'd like to introduce to key opinion leaders for this session. Joanne Kurtzberg, who's Professor of Pediatrics and Pathology at Duke University School of Medicine, and we have by video link Dr. Susan Prockop, who's Director of the Clinical and Translational Research in the stem cell transplant program at the Dana Farber in Boston. So let me start by asking Joanne, who's been a strong supporter of our program for...

Let me address the question to us. Susan, maybe you could talk a little bit about your experiences since the product has been launched. And in particular, if you could just give us your insights into how you think the product is being used immediately after steroids at your place. And just given the safety considerations and how safe it is, et cetera, is there any reason why people would not want to use it as quickly...

What analysts pressed on

Analysts expressed concerns regarding the competitive landscape for chronic low back pain treatments and the potential for redosing strategies post-approval. There were also inquiries about the company's ability to differentiate its therapies in a crowded market.

Main topics on the call

• Revenue Growth and Commercial Strategy — Mesoblast reported net revenues of $30.3 million for the quarter, with total revenues from Ryoncil approaching $100 million since its launch. Management stated, "We have established the capability to scale with a clear p...
• Expansion into Adult Indications — The company is initiating a Phase III trial for adult steroid-refractory acute graft versus host disease, which is expected to triple the franchise. Management noted, "The market size in adult is approximately 3x larger ...
• Pivotal Trials for Chronic Low Back Pain — Enrollment for the pivotal trial in chronic low back pain is set to complete this month, with top-line results expected in mid-2027. Management stated, "We are very confident we will be able to achieve this trial's prima...
• Financial Discipline and Cash Management — Mesoblast emphasized a disciplined approach to cash management, projecting full fiscal year revenues between $110 million and $120 million while controlling costs. Management highlighted, "Our cash burn is actually going...

Read the full Mesoblast Limited transcript (April 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 34 Mesoblast Limited earnings call transcripts on record, spanning February 26, 2020 to August 26, 2026. Based on this history, Mesoblast Limited reports quarterly. The most recent call on file is dated August 26, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

MSB

Exchange

ASX

Country

AU

Sector

Health Care

Industry

Biotechnology

Calls on record

34

First call

February 26, 2020

Most recent

August 26, 2026

Reporting cadence

quarterly